Groundbreaking site benchmarking data proves that sites with more staff certified are more profitable than those with fewer staff certified.
Groundbreaking site benchmarking data proves that sites with more staff certified are more profitable than those with fewer staff certified.
“This data validates that investing in ACRP Certification of site staff will attract more studies and lead to greater site profitability,” says James D. Thomasell, Executive Director of ACRP. “This is definitive data on how ACRP Certification positively impacts performance at the site level.”
Data shows that:
· Clinical trial sites with greater numbers of certified staff initiated three times as many trials (20.9 on average) as those with fewer certified staff (6.9) in 2013;
· Clinical trial sites with greater numbers of certified staff averaged $1.6 million in study grants invoiced in 2013, versus $466,000 for sites with fewer certified staff; and
· Clinical trial sites with greater numbers of certified staff reported greater operating profit (18.2%) than those with fewer certified staff (13.9%) in 2013.
This data, which is the result of a joint site survey conducted by ACRP and CenterWatch, a leading provider of clinical trials information, was announced this weekend as part of the inaugural ACRP Site Strategy Forum in San Antonio, Texas, as part of the ACRP 2014 Global Conference & Exhibition.
“We included certification as a component of the site survey in order to establish a benchmark for sites and can now confirm a direct and significant correlation between certification and site performance,” says Kenneth Getz, Founder and Owner of CenterWatch and Director of Sponsored Research Programs for the Center for the Study of Drug Development at the Tufts University School of Medicine.
“I am so pleased that CenterWatch and ACRP collaborated on the site operations survey as part of our overall partnership,” says Joan A. Chambers, COO of CenterWatch, “and are able to provide survey results relating not only to certification, but to risk based monitoring and overall site operations.”
Final benchmarking data will be available mid-summer 2014.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.